Новости фондового рынка США – NYSE, NASDAQ на 22.06.2017

Вниз
Реакция на earnings/guidance:

• SCS -16.6%, ACN -3%, CACI -1.4%

Другие новости

• ESNC -26.1% (to offer newly issued shares of common stock pursuant to an underwritten public offering)
• KMDA -26% (withdraws Marketing Authorization Application for its proprietary inhaled Alpha-1 Antitrypsin therapy for the treatment of Alpha-1 Antitrypsin Deficiency with the European Medicines Agency)
• JCAP -8.4% (announces commencement of public offering of common stock)
• WB -7.6% (vague chatter that regulators may have ordered the company to halt audio and video programming services)
• PZRX -5% (files mixed securities shelf offering with proposed maximum aggregate offering price of $15 mln)
• SINA -5% (in sympathy with WB)
• SBPH -4.8% (announces proposed public offering of common stock)
• TMHC -4.1% (prices 10 mln shares of common stock)
• STM -3.4% (announces a $1.5 bln dual-tranche offering of New Convertible Bonds, the early redemption of its 2019 Convertible Bonds, the launch of a share buy-back program)
• JD -1.3% (invests $397 million in Farfetch)

Комментарии аналитиков:

• CNK -0.8% (downgraded to Underperform at Credit Suisse)

Вверх  
Реакция на earnings/guidance:

• ORCL +11.3%, CMC +8.6%, HAIN +5.5%, CO +4.5%, APOG +4.1%

M&A news:

• SPLS +6.8% (Sycamore Partners nearing M&A deal to purchase SPLS, according to Reuters)

Другие новости

• TROV +13.7% (enters into agreement with a worldwide, premier biopharmaceutical company to provide Trovera urine circulating tumor DNA biomarker tests and services)
• OVAS +8.2% (appoints Christopher Kroeger as CEO effective September 1; will restructure its organization)
• NRZ +3.1% ( increases quarterly dividend to $0.50 per common share from $0.48 per common share)
• NVS +2.7% (reports Phase 3 data for ACZ885 demonstrating reduction in cardiovascular risk)
• SHPG +2.3% (receives EMA Validation of Veyvondi)
• FGEN +1% (confirms receipt of Orphan Drug Designation by the FDA for Pamrevlumab)

Комментарии аналитиков:

• ATVI +1.3% (target raised to $70 from $60 at Oppenheimer)
• VLO +1.2% (upgraded to Buy from Hold at Jefferies)

Сканер Акций :